medication-adherence | CARLAT PUBLISHING

Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?

May 4, 2021

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Textbooks tell us that patients with bipolar I disorder need to take mood stabilizers for life. But what are the real risks of stopping these medications? A new meta-analysis provides some clarity.

Are SSRIs Associated With Increased Rates of Violence?

February 3, 2021

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

SSRIs are often used to reduce irritability, but questions about they can cause violence have loomed over these antidepressants since the early 1990’s. This new study, with 700,000 patients followed over 7 years, suggests they can.

When to Stop Addiction Treatment: How Long Is Enough?

December 10, 2020

Michael Weaver, MD, FASAM.

Michael Weaver, MD, FASAM. Professor and medical director at the Center for Neurobehavioral Research on Addictions, University of Texas Medical School. Dr. Weaver has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Addiction is often lifelong phenomenon, but many patients may still wish to end treatment. We discuss the reasons why a patient might ask to “complete” their treatment and provide you with strategies for talking with patients about ceasing therapeutic treatments for substance use disorders.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

“What About the Implant, Doc?” Appraising Various Formulations of Buprenorphine

August 6, 2020

Edmund S. Higgins, MD.

Edmund S. Higgins, MD. Clinical Associate Professor of Psychiatry and Family Medicine, MUSC, Charleston, SC. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buprenorphine can be administered via intravenous, transdermal, sublingual, buccal, and implanted formulations. We appraise the evidence for various formulations and suggest certain populations for which certain formulations may be a better choice.

A New Way to Talk to Patients about Medication

August 30, 2019

Shawn Christopher Shea, MD

Shawn Christopher Shea, MD

Director of the Training Institute for Suicide Assessment and Clinical Interviewing. Internationally recognized innovator in the fields of clinical interviewing and suicide prevention and author of seven books, several of which are included in Doody’s Core List of the most important books in psychiatry and medicine. Dr. Shea has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Shawn Christopher Shea, MD has been fine-tuning the art of doctor-patient communications for over 30 years. He shares his tips on talking about medications.